ATE475652T1 - Chinazolinderivate - Google Patents
ChinazolinderivateInfo
- Publication number
- ATE475652T1 ATE475652T1 AT02700688T AT02700688T ATE475652T1 AT E475652 T1 ATE475652 T1 AT E475652T1 AT 02700688 T AT02700688 T AT 02700688T AT 02700688 T AT02700688 T AT 02700688T AT E475652 T1 ATE475652 T1 AT E475652T1
- Authority
- AT
- Austria
- Prior art keywords
- quinazoline derivatives
- agent
- compound
- theprophylaxis
- racemate
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001045827 | 2001-02-21 | ||
| JP2001353525 | 2001-11-19 | ||
| PCT/JP2002/001575 WO2002066445A1 (fr) | 2001-02-21 | 2002-02-21 | Derives de la quinazoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE475652T1 true ATE475652T1 (de) | 2010-08-15 |
Family
ID=26609852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02700688T ATE475652T1 (de) | 2001-02-21 | 2002-02-21 | Chinazolinderivate |
Country Status (10)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| HRP20080329T3 (en) | 2003-09-16 | 2008-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| PT1667992E (pt) * | 2003-09-19 | 2007-04-30 | Astrazeneca Ab | Derivados de quinazolina |
| DE602004004811T2 (de) * | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
| JP2007506716A (ja) * | 2003-09-25 | 2007-03-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CA2545711A1 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
| EP1690856A4 (en) * | 2003-11-28 | 2007-09-05 | Aveo Pharmaceuticals Inc | CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF |
| WO2005075439A1 (en) | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
| RS52119B (en) | 2004-05-06 | 2012-08-31 | Warner-Lambert Company Llc | 4-phenylamino-HINAZOLIN-6-IL-STARCHES |
| US20080200433A1 (en) * | 2004-09-01 | 2008-08-21 | Tsuyoshi Suzuki | Molecular Chaperone Function Regulator |
| CN101124228B (zh) | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | 用作抗肿瘤药物的吡唑并嘧啶化合物 |
| US8202879B2 (en) | 2005-02-23 | 2012-06-19 | Shionogi & Co., Ltd. | Quinazoline derivatives having tyrosine kinase inhibitory activity |
| MX2007010399A (es) | 2005-02-26 | 2007-09-25 | Astrazeneca Ab | Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina. |
| WO2006106721A1 (ja) * | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| JP2009508918A (ja) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物 |
| EP2010183A4 (en) * | 2006-03-03 | 2010-08-25 | Aveo Pharmaceuticals Inc | PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| DK2245026T3 (da) | 2008-02-07 | 2012-10-15 | Boehringer Ingelheim Int | Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling |
| EA019183B1 (ru) * | 2008-05-13 | 2014-01-30 | Астразенека Аб | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| MX2012010557A (es) * | 2010-03-16 | 2012-10-05 | Merck Patent Gmbh | Morfolinilquinazolinas. |
| KR20220031732A (ko) * | 2011-03-04 | 2022-03-11 | 뉴젠 세러퓨틱스 인코포레이티드 | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 |
| CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| CN103254143B (zh) * | 2013-04-26 | 2015-10-07 | 浙江工业大学 | 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用 |
| CN104119350B (zh) | 2013-04-28 | 2017-04-12 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| CN105916851A (zh) | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
| AU2016334141B2 (en) | 2015-10-09 | 2019-12-19 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| CN110430881A (zh) * | 2017-01-30 | 2019-11-08 | 盐野义制药株式会社 | 含有喹唑啉衍生物的固体制剂 |
| CN111212837A (zh) | 2017-04-07 | 2020-05-29 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
| WO2019233459A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| CN110577514B (zh) * | 2018-06-08 | 2022-07-05 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| US20220298120A1 (en) * | 2019-08-15 | 2022-09-22 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3134236B2 (ja) | 1992-01-30 | 2001-02-13 | 株式会社林原生物化学研究所 | α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム |
| JP2994165B2 (ja) | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
| GEP20012442B (en) | 1996-04-12 | 2001-05-25 | Warner Lambert Co | Irreversible Inhibitors of Tyrosine Kinases |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| UA73990C2 (en) * | 2000-06-22 | 2005-10-17 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cells growth |
| EP1690856A4 (en) * | 2003-11-28 | 2007-09-05 | Aveo Pharmaceuticals Inc | CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF |
-
2002
- 2002-02-21 TW TW091102988A patent/TWI309647B/zh active
- 2002-02-21 JP JP2002565961A patent/JP4285996B2/ja not_active Expired - Fee Related
- 2002-02-21 DE DE60237145T patent/DE60237145D1/de not_active Expired - Lifetime
- 2002-02-21 US US10/468,788 patent/US7294629B2/en not_active Expired - Fee Related
- 2002-02-21 CN CNB028052609A patent/CN1264824C/zh not_active Expired - Fee Related
- 2002-02-21 KR KR1020037011020A patent/KR100861486B1/ko not_active Expired - Fee Related
- 2002-02-21 AT AT02700688T patent/ATE475652T1/de not_active IP Right Cessation
- 2002-02-21 WO PCT/JP2002/001575 patent/WO2002066445A1/ja active Application Filing
- 2002-02-21 EP EP02700688A patent/EP1369418B1/en not_active Expired - Lifetime
- 2002-02-21 CA CA002442742A patent/CA2442742A1/en not_active Abandoned
-
2007
- 2007-06-28 US US11/819,679 patent/US20070265260A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2442742A1 (en) | 2002-08-29 |
| JP4285996B2 (ja) | 2009-06-24 |
| EP1369418A4 (en) | 2005-09-14 |
| TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-05-11 |
| US20040116422A1 (en) | 2004-06-17 |
| KR100861486B1 (ko) | 2008-10-02 |
| EP1369418A1 (en) | 2003-12-10 |
| US7294629B2 (en) | 2007-11-13 |
| DE60237145D1 (de) | 2010-09-09 |
| EP1369418B1 (en) | 2010-07-28 |
| CN1264824C (zh) | 2006-07-19 |
| US20070265260A1 (en) | 2007-11-15 |
| KR20030086269A (ko) | 2003-11-07 |
| JPWO2002066445A1 (ja) | 2004-06-17 |
| WO2002066445A1 (fr) | 2002-08-29 |
| CN1492860A (zh) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60237145D1 (de) | Chinazolinderivate | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| BRPI0209216B8 (pt) | derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos | |
| ATE223378T1 (de) | Prolineamid-derivate | |
| EA200500508A1 (ru) | Диариловые эфиры в качестве антагониста опиоидного рецептора | |
| WO2001019829A3 (en) | Pyrazolopyrimidines as therapeutic agents | |
| ATE450533T1 (de) | Carboxamidderivate | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| NO20051263L (no) | Ny anvendelse av benzotiazolderivater | |
| EA200801308A1 (ru) | Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик | |
| BRPI0417714A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA200301276A1 (ru) | Новые производные сульфоновых кислот | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| NO20032261D0 (no) | Medisinske preparater | |
| SE0102440D0 (sv) | New compound | |
| NO20052698L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser. | |
| ATE390923T1 (de) | Topoisomerase-giftmittel | |
| ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
| ATE326451T1 (de) | Chinazolin derivate und therapeutische verwendungen davon | |
| ATE287397T1 (de) | Chinoline derivate und ihre anwendung als antitumor agentien | |
| TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
| ATE293961T1 (de) | Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie | |
| SE9900190D0 (sv) | New compounds | |
| SE0301371D0 (sv) | New Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |